These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9723294)

  • 1. Optimization of cyclosporine therapy in liver transplantation.
    Pollard SG; Lodge JP
    Transplant Proc; 1998 Aug; 30(5):1816-8. PubMed ID: 9723294
    [No Abstract]   [Full Text] [Related]  

  • 2. Benefits of cyclosporine microemulsion (Neoral) C(2) monitoring are sustained at 1 year in de novo liver transplant recipients.
    Lake JR;
    Transplant Proc; 2001; 33(7-8):3092-3. PubMed ID: 11750328
    [No Abstract]   [Full Text] [Related]  

  • 3. Improving the oral absorption of cyclosporine in malabsorbers: a review of the Neoral Compassionate Need Program.
    Mueller EA; Kovarik JM; Pittrow D
    Transplant Proc; 1998 Aug; 30(5):1691-3. PubMed ID: 9723246
    [No Abstract]   [Full Text] [Related]  

  • 4. Absorption of cyclosporine Neoral early after liver transplantation: influence of bile on oral absorption.
    Oldhafer K; Haller GW; Kattner A; Winkler M; Maibücher A; Färber L; Bechstein WO; Ringe B; Neuhaus P; Pichlmayr R
    Transplant Proc; 1996 Aug; 28(4):2237-8. PubMed ID: 8769210
    [No Abstract]   [Full Text] [Related]  

  • 5. Importance of cyclosporine pharmacokinetics to clinical outcomes after liver transplantation. Canadian Liver Transplant Study Group.
    Transplant Proc; 1998 Aug; 30(5):1826-7. PubMed ID: 9723297
    [No Abstract]   [Full Text] [Related]  

  • 6. Change of conventional cyclosporine to neoral cyclosporine formulation in long-term liver transplant recipients.
    Diliz HS; Olivera MA; Kershenobich D; Mercado MA; Orozco H
    Transplant Proc; 1996 Dec; 28(6):3348-50. PubMed ID: 8962302
    [No Abstract]   [Full Text] [Related]  

  • 7. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
    Shah MB; Martin JE; Schroeder TJ; First MR
    Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclosporine pharmacology.
    Lee JI; Canafax DM
    Transplant Proc; 1996 Aug; 28(4):2156-8. PubMed ID: 8769185
    [No Abstract]   [Full Text] [Related]  

  • 9. Uses of Neoral in pediatric liver transplantation.
    McDiarmid SV
    Transplant Proc; 1996 Aug; 28(4):2264-6. PubMed ID: 8769220
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients.
    Cooney GF; Lum BL; Meligeni JA; Dunn SP
    Transplant Proc; 1996 Aug; 28(4):2270-2. PubMed ID: 8769222
    [No Abstract]   [Full Text] [Related]  

  • 11. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation.
    Holmberg C; Laine J; Jalanko H; Leijala M; Hoppu K
    Transplant Proc; 1996 Aug; 28(4):2262-3. PubMed ID: 8769219
    [No Abstract]   [Full Text] [Related]  

  • 12. Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application?
    Haller GW; Winkler M; Bechstein WO; Oldhafer KJ; Ringe B; Maibücher A; Färber L; Pichlmayr R; Neuhaus P
    Transplant Proc; 1996 Aug; 28(4):2239-40. PubMed ID: 8769211
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetic comparison of two cyclosporine A formulations, SangCya (Sang-35) and Neoral, in stable adult liver transplant recipients.
    Fisher RA; Pan SH; Rossi SJ; Schroeder TJ; Irish WD; Canafax DM; Lopez RR
    Transplant Proc; 1999; 31(1-2):394-5. PubMed ID: 10083157
    [No Abstract]   [Full Text] [Related]  

  • 14. [What significance has the C(2) value in the treatment with cyclosporin A?].
    Pham VV; Stichtenoth DO; Frölich JC
    Dtsch Med Wochenschr; 2004 Mar; 129(13):706. PubMed ID: 15026970
    [No Abstract]   [Full Text] [Related]  

  • 15. The evolution of therapeutic drug monitoring of cyclosporine.
    Kahan BD
    Transplant Proc; 2001; 33(7-8):3086-8. PubMed ID: 11750326
    [No Abstract]   [Full Text] [Related]  

  • 16. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J
    Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical benefit of monitoring cyclosporine C2 and C4 in long-term liver transplant recipients.
    Barakat O; Peaston R; Rai R; Talbot D; Manas D
    Transplant Proc; 2002 Aug; 34(5):1535-7. PubMed ID: 12176472
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus.
    Oellerich M; Armstrong VW; Schütz E; Shaw LM
    Clin Biochem; 1998 Jul; 31(5):309-16. PubMed ID: 9721427
    [No Abstract]   [Full Text] [Related]  

  • 19. NOF-11: a one-year randomized double-blind comparison of Neoral versus Sandimmune in pediatric liver transplantation.
    Alvarez F; Atkison P; Grant D; Jones A; Kim P; Kneteman N; Laurin L; Martin S; Paradis K; Shapiro J; Smith L; Superina R; Tan A
    Transplant Proc; 1998 Aug; 30(5):1961. PubMed ID: 9723352
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclosporine versus cyclosporine microemulsion in pediatric liver transplant recipients.
    Loss GE; Brady L; Grewal HP; Siegel CT; Mead J; Bruce DS; Cronin DC; Woodle ES; Newell KA; Thistlethwaite JR; Millis JM
    Transplant Proc; 1998 Jun; 30(4):1435-6. PubMed ID: 9636581
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.